

samumed news

January 2019

Oncology (ONC) Program Update



- The FDA granted us orphan drug designation (ODD) for pancreatic cancer

Osteoarthritis (OA) Program Update



- We have dosed the first patients in a phase 2, multiple injection safety and tolerability study on SM04690

Corporate News



- We have hired the following senior position:
 - Thomas Bicsak, PhD, VP Regulatory Affairs